By the end of 2022, 23 biosimilars will have launched, and 15 more will have been approved by the Federal Drug Administration (FDA). Nearly all of the launched biosimilars are physician administered products and have buy-and-bill dynamics at play.  As of 2022, the only biosimilar medications managed through the pharmacy benefit have been limited to insulins, however, that will soon change when one of the largest brands in the history of pharmaceuticals – Humira – faces biosimilar adalimumab competition in January 2023. Download this white paper to learn more.